^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LINC02381 (Long Intergenic Non-Protein Coding RNA 2381)

    i
    Other names: LINC02381, Long Intergenic Non-Protein Coding RNA 2381, LOC400043, NONHSAG011276.2, NONHSAG011275.2, HSALNG0091335, Lnc-HOXC4-4
    Associations

    News

    Trials
    4ms
    The Role of LINC02381 in Modulating Cisplatin Resistance in Ovarian Cancer: A Bioinformatics Approach. (PubMed, Iran J Allergy Asthma Immunol)
    Lastly, through an examination of its interactions with microRNA and protein networks, we identified LINC02381 as a ceRNA implicated in cisplatin resistance. Our findings suggest that LINC02381 may influence cisplatin sensitivity in ovarian cancer and establish a basis for further experimental validation, including molecular assays or in vivo analyses, and suggest the potential therapeutic targeting of LINC02381 to combat chemoresistance.
    Journal
    |
    LINC02381 (Long Intergenic Non-Protein Coding RNA 2381)
    |
    cisplatin
    4ms
    The LINC02381/let-7g-5p/THBS1 Signaling Axis Modulates Cellular Proliferative Activity in Osteosarcoma. (PubMed, Cancers (Basel))
    LINC02381 promotes OA progression by acting as a ceRNA for let-7g-5p, thereby upregulating THBS1 expression. This signaling axis represents a potential therapeutic target for OS.
    Journal
    |
    THBS1 (Thrombospondin 1) • LINC02381 (Long Intergenic Non-Protein Coding RNA 2381)
    5ms
    LncRNA LINC02381/miR-133b axis promotes tumorigenesis and predicts survival in pancreatic cancer. (PubMed, Discov Oncol)
    Elevated levels of LINC02381 are associated with diminished survival outcomes in pancreatic cancer patients, suggesting its potential as a prognostic biomarker for this malignancy. These findings warrant further investigation to elucidate the role of LINC02381 in pancreatic cancer progression and patient prognosis.
    Journal
    |
    LINC02381 (Long Intergenic Non-Protein Coding RNA 2381) • MIR133B (MicroRNA 133b)
    1year
    Bioinformatics-driven Identification of lncRNA LINC02381 in Mediating Cisplatin Resistance via IL-12 Induced Wnt/TCF7 Signaling in Ovarian Cancer. (PubMed, Iran J Allergy Asthma Immunol)
    Our findings suggest that targeting this regulatory pathway may offer promising therapeutic strategies to overcome chemotherapy resistance, paving the way for improved treatment outcomes in patients with ovarian cancer. Future research should focus on validating these mechanisms and exploring potential interventions that disrupt this feedback loop.
    Journal
    |
    LINC02381 (Long Intergenic Non-Protein Coding RNA 2381) • TCF7 (Transcription Factor 7)
    |
    cisplatin
    1year
    Identification and validation of LINC02381 as a biomarker associated with lymph node metastasis in esophageal squamous cell carcinoma. (PubMed, Transl Cancer Res)
    LINC02381 may serve as a biomarker for predicting LNM. Our risk model can assist in predicting LNM in clinical practice, inform the decision to implement neoadjuvant therapy before surgery, and therefore improve prognosis.
    Journal
    |
    LINC02381 (Long Intergenic Non-Protein Coding RNA 2381)
    1year
    Development and experimental validation of a senescence-related long non-coding RNA signature for prognostic prediction and immune microenvironment characterization in gastric cancer patients. (PubMed, J Gastrointest Oncol)
    Finally, the qRT-PCR validation revealed that the AP000695.2 and AP003392.1 expression levels were significantly higher in the tumor tissues and GC cell lines than the normal tissues and normal human gastric epithelial cell line, whereas the opposite pattern was found for LINC02381. The development of the SenLncSig provided a potential tool for improving patient prognosis predictions and offered preliminary insights into predicting the efficacy of GC immunotherapy.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • LINC02381 (Long Intergenic Non-Protein Coding RNA 2381)
    |
    TMB-H
    over2years
    Bioinformatics analysis of hedgehog interacting protein in colorectal cancer: a study based on GEO data and TCGA data. (PubMed, BMC Gastroenterol)
    In addition, HHIP expression level was significantly correlated with tumor immune cell infiltration, biomarkers of immune cells, and immune checkpoint expression. Overall, our findings clarified ncRNAs-mediated down-regulation of HHIP which was associated with poor prognosis and tumor immune infiltration in CRC.
    Journal
    |
    LINC02381 (Long Intergenic Non-Protein Coding RNA 2381)
    over2years
    FERROPTOSIS-RELATED LNCRNAS AS NOVEL PROGNOSTIC BIOMARKERS FOR COLON ADENOCARCINOMA (UEGW 2023)
    A signature based on eight ferroptosis-related lncRNAs is efficient in predicting the prognosis of patients with COAD. The eight lncRNAs may be novel prognostic and therapeutic biomarkers for COAD. The specific mechanism of how ferroptosis-related lncRNAs affects tumor biological behavior remains to be researched.
    IO biomarker
    |
    CD27 (CD27 Molecule) • SNHG16 (Small Nucleolar RNA Host Gene 16) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • LINC02381 (Long Intergenic Non-Protein Coding RNA 2381)
    3years
    LINC02381 suppresses cell proliferation and promotes apoptosis via attenuating IGF1R/PI3K/AKT signaling pathway in breast cancer. (PubMed, Funct Integr Genomics)
    The reduced migration rate of these cells was also verified through wound healing assay and RT-qPCR against the EMT-involved genes. Our data show that LINC02381 exerts its tumor suppressor effect at least partly through attenuation of the IGF1R/PI3K/AKT signaling pathway, which originated from IGF1R downregulation.
    Journal
    |
    CASP3 (Caspase 3) • CASP7 (Caspase 7) • ANXA5 (Annexin A5) • LINC02381 (Long Intergenic Non-Protein Coding RNA 2381)
    3years
    Pyroptosis-related lncRNAs: A novel prognosis signature of colorectal cancer. (PubMed, Front Oncol)
    Three independent methods were applied to predict PRL-related sensitivity to chemotherapeutic drugs. Our comprehensive analysis of PRLs in CRC patients demonstrates a potential role of PRLs in predicting response to treatment and prognosis of CRC patients, which may provide a better understanding of molecular mechanisms underlying CRC pathogenesis and facilitate the development of effective immunotherapy.
    Journal • IO biomarker
    |
    MSI (Microsatellite instability) • LINC02381 (Long Intergenic Non-Protein Coding RNA 2381)
    over3years
    Gene expression profiling of breast cancer brain metastasis shows enrichment for non-luminal subtypes with potential prognostic implications (SABCS 2022)
    Non-luminal intrinsic subtypes are extensively represented in resected BCBMs, even if clinically classified as HR+/HER2-. Our data suggest that basal-like genomic features might be enriched in BCBMs and might be associated with worse survival. Distribution of PAM50 intrisic subtyping on the 65 brain metastases evaluated according to hormone receptor (HR) and HER2 status
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • NOTCH1 (Notch 1) • IL6 (Interleukin 6) • CAV1 (Caveolin 1) • CDK6 (Cyclin-dependent kinase 6) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • KRT17 (Keratin 17) • GAS1 (Growth Arrest Specific 1) • RUNX3 (RUNX Family Transcription Factor 3) • CDH3 (Cadherin 3) • FOXC1 (Forkhead Box C1) • KRT5 (Keratin 5) • SNAI1 (Snail Family Transcriptional Repressor 1) • CKB (Creatine Kinase B) • CRYAB (Crystallin Alpha B) • GABRP (Gamma-Aminobutyric Acid Type A Receptor Subunit Pi) • LINC02381 (Long Intergenic Non-Protein Coding RNA 2381) • SPRY2 (Sprouty RTK Signaling Antagonist 2)
    |
    HER-2 negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • nCounter® Breast Cancer 360™ Panel